The global peptide therapy market is undergoing one of the most dramatic structural transformations in pharmaceutical history. Driven by the GLP-1 revolution — the extraordinary commercial success of glucagon-like peptide-1 receptor agonist drugs for diabetes and obesity — the market was worth USD 84.2 billion in 2025 and is expected to grow at a CAGR of 14.74% to reach USD 196.5 billion by 2031. To contextualise this scale: peptide therapeutics are on track to surpass oncology as the world's largest therapeutic market category by 2028–2030 — making this the fastest-growing major drug class in pharmaceutical history.

The market's dominant force is the GLP-1/GIP Receptor Agonist Therapy segment, which accounted for 65.8% of global peptide market value in 2026, growing at 16.43% CAGR by value and 23.95% by volume through 2031. This segment is led by a duopoly: Novo Nordisk's semaglutide (Ozempic for diabetes, Wegovy for obesity) and Eli Lilly's tirzepatide (Mounjaro for T2D, Zepbound for obesity and sleep apnea) together commanded 57.4% of the overall peptide therapy market in 2026 — an extraordinary concentration in a USD 84.2 billion market. Both companies posted record revenues in 2024: Novo Nordisk DKK 290.4 billion (~USD 41 billion, +26%) and Eli Lilly USD 45.0 billion (+32%), with Lilly guiding for USD 58–61 billion in 2025.

North America leads with 49.8% market share in 2026, with US GLP-1 prescriptions reaching USD 32 billion in 2024 alone. According to the Navadhi Global Peptide Therapy Market Strategic Research Report 2026-2031 Asia-Pacific is the fastest-growing region at 17.07% CAGR, driven by China's 140 million diabetics, Japan's post-PMDA approvals of Ozempic and Wegovy, and India emerging as the fastest-growing sub-market at 19.89% CAGR, leveraging GLP-1 biosimilar production. Europe holds 24.4% share growing at 12.59% CAGR.

Beyond GLP-1, the market encompasses peptide cancer therapies (Oncology Peptide Therapy at 4.1% share, 11.79% CAGR), somatostatin analogues for neuroendocrine tumours, GnRH agonists/antagonists for hormone-sensitive cancers, radioligand therapy, and reproductive medicine peptides — each representing strategically important niches with their own competitive dynamics.

Note: Rankings reflect composite of total group revenue, peptide-specific revenue share, GLP-1 pipeline position, and strategic importance. Novo Nordisk and Eli Lilly are ranked #1-2 based on GLP-1/GIP market dominance (57.4% combined share). Ferring Pharmaceuticals is private; revenue is estimated. All other companies are publicly listed with audited financials. Revenue figures are FY2024 unless noted.

• Global peptide therapy market value (2025): USD 84.2 billion — CAGR 14.74% (2026–2031) → USD 196.5 billion by 2031
• Global peptide therapy volume (2025): 20.2 billion dosage units — volume CAGR 21.24% → 65.5 billion units by 2031; volume growing faster than value, indicating penetration into price-sensitive populations
• GLP-1/GIP Receptor Agonist Therapy: 65.8% of market by value (2026); CAGR 16.43% by value and 23.95% by volume through 2031
• Novo Nordisk + Eli Lilly combined GLP-1 market share: 57.4% of total peptide therapy market in 2026 — a duopoly of extraordinary concentration
• Oncology Peptide Therapy: 4.1% market share; CAGR 11.79% value / 17.98% volume — second fastest-growing segment
• Largest application: Diabetes & Obesity (GLP-1 adoption for obesity unlocking massive new patient populations via Wegovy and Zepbound)
• North America: 49.8% market share (2026); US GLP-1 prescriptions = USD 32 billion in 2024 — critical revenue driver
• Asia-Pacific: fastest-growing region at 17.07% CAGR by value and 21.43% by volume; China (140M diabetics), Japan (Ozempic 2021, Wegovy 2023)
• India: fastest-growing APAC sub-market at 19.89% CAGR — GLP-1 biosimilar production and growing middle class
• Europe: 24.4% market share (2026); 12.59% CAGR; Germany 16.5%, UK 13.4%, France 13.1% of European market
• Middle East & Africa: 16.26% CAGR — Saudi Arabia highest T2D prevalence globally at 24% (IDF 2024); UAE premium market
• Peptide therapy projected to surpass oncology as world's largest therapeutic market category by 2028–2030

Novo Nordisk A/S (NASDAQ: NVO; CSE: NOVO B) is the world's dominant peptide therapy company and the single most consequential participant in the GLP-1 revolution that has transformed pharmaceutical markets since 2021. Headquartered in Bagsvaerd, Denmark, Novo Nordisk was founded in 1923 specifically around insulin — itself a peptide — and has spent a century perfecting the science, manufacturing, and commercialisation of peptide therapeutics. Its GLP-1 receptor agonist portfolio, anchored by semaglutide in its injectable form (Ozempic for diabetes, Wegovy for obesity) and oral form (Rybelsus), generated approximately USD 26 billion in combined sales in 2024, making semaglutide the world's highest-revenue drug. The company became Europe's most valuable publicly listed company in 2023, a position it has maintained into 2025.

Novo Nordisk's FY2024 results confirmed the structural nature of the GLP-1 demand wave: total revenues grew 26% to DKK 290.4 billion (approximately USD 41 billion), with Obesity care revenues up 56% to DKK 65.1 billion (approximately USD 8.2 billion). Ozempic sales grew 26% to DKK 120.3 billion (approximately USD 17 billion). The pipeline confirms the company is not standing still: the REDEFINE 1 Phase 3 trial of CagriSema — a fixed-ratio combination of semaglutide and the amylin analogue cagrilintide — demonstrated 22.7% weight loss at 68 weeks, superior to semaglutide alone; while semaglutide 7.2mg in the STEP UP trial achieved 20.7% weight loss, reinforcing the company's ability to drive performance improvements on its core molecule. To alleviate the supply constraints that have limited growth, Novo Nordisk completed the acquisition of three fill-finish manufacturing sites from Catalent in December 2024.

Quick Facts

• HQ: Bagsvaerd, Denmark
• FY2024 Revenue: DKK 290.4B (~USD 41.0B) FY2024 (+26% YoY); Ozempic: USD ~17B; Wegovy: USD ~8.2B
• Key Peptide Products: Semaglutide (Ozempic, Wegovy, Rybelsus), insulin degludec (Tresiba), liraglutide (Victoza, Saxenda), CagriSema (pipeline), semaglutide 7.2mg (pipeline)
• Therapeutic Segments: Diabetes Care (GLP-1, Insulins); Obesity Care (Wegovy); Rare Disease (haematology, rare endocrine)
• 2024–2026 Update: Revenue grew 26% to USD 41B in FY2024; Ozempic +26% YoY to USD 17B; Wegovy obesity sales +56% to USD 8.2B; CagriSema Phase 3 (REDEFINE 1): 22.7% weight loss; STEP UP semaglutide 7.2mg: 20.7% weight loss; acquired Catalent manufacturing sites Dec 2024

Eli Lilly and Company (NYSE: LLY) is the #2-ranked company in the global peptide therapy market and the most important commercial challenger to Novo Nordisk's GLP-1 dominance. Founded in Indianapolis in 1876, Eli Lilly had already built a formidable position in diabetes and oncology when tirzepatide — its dual GIP/GLP-1 receptor agonist — became the fastest-launched pharmaceutical product in history. Tirzepatide's dual mechanism of action, activating both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, produces superior metabolic effects compared to GLP-1-only approaches — demonstrated in head-to-head clinical data and confirmed commercially by its rapid market penetration.

Eli Lilly's FY2024 performance was extraordinary: total revenues of USD 45.0 billion, up 32% year-on-year, driven by Mounjaro (approximately USD 11.5 billion full-year, a more than 4× increase from 2023) and Zepbound (approximately USD 4.9 billion for its first full year of obesity indication sales, including the landmark Q4 figure of USD 1.9 billion). Lilly's 2025 guidance of USD 58–61 billion implies continued 32% growth momentum, validated by the SURMOUNT-5 Phase 3b head-to-head trial result: Zepbound demonstrated 47% greater relative weight loss compared to Wegovy — the most commercially consequential head-to-head data in the obesity market. Zepbound's December 2024 FDA approval for obstructive sleep apnea (OSA) opens an entirely new patient population, with tirzepatide now the first approved pharmacotherapy for OSA. The pipeline further strengthens with retatrutide (GLP-1/GIP/glucagon triple agonist) in Phase 3.

Quick Facts

• HQ: Indianapolis, Indiana, USA
• FY2024 Revenue: USD 45.0B FY2024 (+32% YoY); Mounjaro: USD ~11.5B; Zepbound: USD ~4.9B; 2025 guidance: USD 58-61B
• Key Peptide Products: Tirzepatide (Mounjaro for T2D, Zepbound for obesity/OSA), dulaglutide (Trulicity), insulin lispro (Humalog), retatrutide GLP-1/GIP/glucagon triple agonist (Phase 3 pipeline)
• Therapeutic Segments: Diabetes & Obesity (Incretin); Oncology; Immunology; Neuroscience
• 2024–2026 Update: FY2024 revenue USD 45B (+32%); Q4 Mounjaro USD 3.5B; Q4 Zepbound USD 1.9B; Zepbound approved for obstructive sleep apnea Dec 2024; SURMOUNT-5 head-to-head: Zepbound 47% greater weight loss vs Wegovy; 2025 guidance USD 58-61B

Novartis AG (NYSE: NVS; SIX: NOVN) ranks third in this report on the strength of its diversified pharmaceutical portfolio and, critically, its position as the global pioneer and leader in radioligand therapy (RLT) — a highly specialised form of peptide-based oncology treatment that uses peptide targeting vectors conjugated to radioactive isotopes to selectively destroy tumour cells. Its two RLT products — Lutathera (lutetium-177 DOTATATE) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and Pluvicto (lutetium-177 PSMA-617) for metastatic castration-resistant prostate cancer — represent the most commercially advanced radioligand therapy platform in the world and occupy the Oncology Peptide Therapy segment, which the report forecasts to grow at 11.79% CAGR through 2031.

Novartis delivered FY2024 net sales of USD 51.7 billion, growth of 11% in USD terms (12% at constant currencies), with core operating income up 22% at constant currencies and core operating margin reaching 38.7% — evidence of significant operating leverage as its growth brands accelerate. Pluvicto grew 42% at constant currencies in FY2024, becoming an increasingly significant revenue contributor as manufacturing capacity constraints that limited early sales have been progressively resolved. The somatostatin analogue franchise — Sandostatin (octreotide) and Signifor (pasireotide) — represents an established peptide therapy presence in the neuroendocrine tumour and Cushing's disease markets. Novartis is investing in expanding Pluvicto's label into pre-taxane prostate cancer (SPLASH trial submission pending), and developing next-generation RLT approaches targeting breast cancer and other tumour types — positioning it to maintain leadership in the highest-growth oncology peptide segment.

Quick Facts

• HQ: Basel, Switzerland
• FY2024 Revenue: USD 51.7B FY2024 (+11% USD, +12% cc); Pluvicto (lutetium-177 PSMA) growing +42% cc; Leqvio +114% cc
• Key Peptide Products: Lutathera (lutetium-177 DOTATATE, oncology peptide receptor radionuclide), Pluvicto (177Lu-PSMA-617), Sandostatin/Signifor (octreotide/pasireotide somatostatin analogues), Leqvio (inclisiran siRNA, category-adjacent)
• Therapeutic Segments: Oncology (radioligand therapy, CDK4/6 inhibitors); Cardiovascular; Immunology; Neuroscience
• 2024–2026 Update: FY2024 net sales +11% USD to USD 51.7B; Pluvicto +42% cc in FY2024; Lutathera growing steadily in NETs; Sandostatin franchise maintaining share vs generic pressure; Radioligand therapy platform building toward prostate + breast cancer expansion

Ipsen SA (Euronext: IPN; ADR: IPSEY) is a French specialty biopharmaceutical company and the most focused pure-play peptide oncology company in the top 10. Founded in 1929, Ipsen built its commercial franchise almost entirely on two foundational peptide drugs: Somatuline (lanreotide), a long-acting somatostatin analogue for gastroenteropancreatic neuroendocrine tumours and acromegaly; and Decapeptyl (triptorelin), a GnRH agonist that suppresses testosterone and oestrogen production for prostate cancer, breast cancer, and endometriosis treatment. These two peptide drugs together contribute approximately EUR 1.65 billion of Ipsen's FY2024 sales — making peptides more central to its business than virtually any other company in the top 10.

Ipsen's FY2024 results confirmed solid execution: total sales of EUR 3,400.6 million (+9.9% at constant currencies), with core operating margin of 32.6%. Somatuline — Ipsen's largest product — grew 5.6% to EUR 1,121.3 million, benefiting from supply shortages affecting generic lanreotide competitors. However, the company has guided for accelerated generic erosion in Somatuline from mid-2025 onwards as additional generics enter the market in the US and Europe — a headwind that will challenge revenue growth through the 2026–2028 period. Decapeptyl (triptorelin) revenue of EUR 535.9 million was flat-to-declining, reflecting generic pricing pressure in key markets. To offset these pressures, Ipsen has successfully launched Iqirvo (elafibranor) for primary biliary cholangitis and Bylvay (odevixibat) for rare liver diseases, and acquired multiple innovative pipeline assets in 2024.

Quick Facts

• HQ: Paris, France
• FY2024 Revenue: EUR 3,400.6M (~USD 3.7B) FY2024 (+9.9% at CER / +8.7% as reported); Somatuline: EUR 1,121M; Decapeptyl: EUR 536M
• Key Peptide Products: Lanreotide (Somatuline — somatostatin analogue for NETs, acromegaly), triptorelin (Decapeptyl — GnRH agonist for prostate/breast cancer, endometriosis), abarelix (predecessor), cabozantinib (Cabometyx — kinase inhibitor)
• Therapeutic Segments: Oncology (NETs, prostate cancer, breast cancer); Neuroscience (Dysport/botulinum); Rare Disease (Bylvay, Iqirvo)
• 2024–2026 Update: FY2024 total sales EUR 3.4B (+9.9% CER); Somatuline EUR 1,121M (+5.6%); Decapeptyl EUR 536M (declining, generic pressure); facing accelerated Somatuline generic erosion from 2025; Iqirvo (PBC) and Bylvay launched successfully; core operating margin 32.6%

AbbVie Inc. (NYSE: ABBV) is ranked fifth in this report on the strength of its enormous overall pharmaceutical scale and its specific contributions to the peptide therapy market through Lupron (leuprolide acetate) — one of the longest-established and most widely prescribed GnRH agonist peptide drugs globally — and Botox Therapeutic, whose botulinum toxin A is a functional peptide neurotoxin used across chronic migraine, overactive bladder, spasticity, and cervical dystonia indications. Spun off from Abbott Laboratories in 2013, AbbVie is among the world's largest pharmaceutical companies by revenue, with FY2024 total revenues of USD 56.3 billion.

AbbVie's FY2024 results demonstrated impressive recovery from the Humira biosimilar erosion crisis: while Humira revenues fell to USD 9.0 billion (from a USD 21 billion peak), the combination of Skyrizi (+51% to USD 11.7 billion) and Rinvoq (+25% to USD 6.0 billion) drove overall top-line growth. In the peptide therapy context, AbbVie's Lupron (leuprolide) franchise — treating prostate cancer, endometriosis, uterine fibroids, and precocious puberty via GnRH agonism — remains a stable legacy contributor, while Botox Therapeutic ($748 million in Q1 2024 alone) constitutes a significant peptide-adjacent revenue stream. AbbVie's pipeline includes pipeline peptide candidates in oncology and immunology, and its acquisition of ImmunoGen — maker of the antibody-drug conjugate Elahere — positions it in an adjacent targeted peptide-linker therapy space that bridges small molecules and biologics.

Quick Facts

• HQ: North Chicago, Illinois, USA
• FY2024 Revenue: USD 56.3B FY2024; Humira USD 9.0B (declining); Skyrizi USD 11.7B (+51% YoY); Rinvoq USD 6.0B; Botox Therapeutic USD ~3.2B
• Key Peptide Products: Lupron (leuprolide — GnRH agonist for prostate cancer, endometriosis, precocious puberty), Synarel (nafarelin), Botox Therapeutic (botulinum toxin A — functional peptide neurotoxin), Venclexta (venetoclax — BCL-2 inhibitor, partnered with Roche)
• Therapeutic Segments: Immunology (Skyrizi, Rinvoq, Humira); Oncology; Neuroscience (Botox Therapeutic, Vraylar, Ubrelvy); Aesthetics
• 2024–2026 Update: FY2024 total revenue USD 56.3B; Skyrizi +51% to USD 11.7B; Humira biosimilar erosion ongoing (USD 9B, down from ~USD 21B peak); Lupron stable in oncology/endocrinology niche; aesthetics (Botox Cosmetic) facing China softness; Cerevel and ImmunoGen acquisitions integrating

AstraZeneca plc (NASDAQ: AZN; LSE: AZ) is ranked sixth in this report on the basis of its large overall pharmaceutical scale, its co-development of Tezspire (tezepelumab, a thymic stromal lymphopoietin targeting biologic with peptide-like mechanism) with Amgen, and its legacy GLP-1 exposure through exenatide (Bydureon). AstraZeneca has deliberately chosen not to directly compete in the GLP-1/GIP receptor agonist space — a strategic choice that, while differentiating, leaves it without exposure to the highest-growth peptide market segment (65.8% of the peptide therapy market; 16.43% CAGR). Instead, AstraZeneca has built one of the industry's strongest oncology franchises through Tagrisso, Imfinzi, Calquence, and Lynparza, and a cardiovascular dominance through Farxiga.

AstraZeneca's FY2024 total revenues of USD 54.1 billion (+18% growth) confirm its position as one of the industry's most consistent growers across multiple therapeutic areas. Tezspire, the TSLP inhibitor co-commercialised with Amgen for severe uncontrolled asthma, recorded combined worldwide sales of USD 843 million for the nine months to September 2024 — growing rapidly as the first biologic targeting TSLP upstream of the inflammatory cascade. In July 2025, AstraZeneca committed to investing USD 50 billion in the United States through 2030 — a manufacturing and R&D commitment that reflects confidence in US market growth. The company's antibody-drug conjugate and bispecific antibody pipeline includes peptide-linker components, and its oncology focus positions it strongly in the Oncology Peptide Therapy segment (11.79% CAGR through 2031).

Quick Facts

• HQ: Cambridge, United Kingdom
• FY2024 Revenue: USD 54.1B FY2024 (+18% YoY); oncology franchise: Tagrisso, Imfinzi, Calquence; cardiovascular: Farxiga USD 7.5B+
• Key Peptide Products: Bydureon/Byetta (exenatide — legacy GLP-1, divested/wound down), Leuplin (leuprolide partnership Japan), Tezspire (tezepelumab — TSLP-targeting biologic; partnered with Amgen), Lokelma (sodium zirconium — non-peptide); oncology bispecifics and ADCs pipeline
• Therapeutic Segments: Oncology (Tagrisso, Imfinzi, Lynparza, Calquence); Cardiovascular/Metabolic (Farxiga); Rare Disease; Respiratory & Immunology
• 2024–2026 Update: FY2024 total revenue USD 54.1B; Tezspire combined sales USD 843M in 9M2024 (with Amgen); announced USD 50B US investment commitment through 2030; building oncology pipeline including peptide-ADCs; limited direct GLP-1 pipeline exposure

Pfizer Inc. (NYSE: PFE) is the world's second-largest pharmaceutical company by 2024 revenue at USD 63.6 billion, but its ranking at #7 in the peptide therapy context reflects the company's limited direct exposure to the GLP-1/GIP revolution that defines the market's highest-growth segment. Pfizer's peptide therapy contributions are largely historical and niche: Genotropin (somatropin, synthetic growth hormone — a 191-amino-acid polypeptide) in paediatric and adult growth hormone deficiency; Somavert (pegvisomant, a growth hormone receptor antagonist) for acromegaly; and a discontinued oral GLP-1 programme (danuglipron) that was terminated in late 2023 due to gastrointestinal tolerability issues that prevented adequate dose escalation.

Pfizer's FY2024 revenue of USD 63.6 billion represents significant decline from its COVID-era peak above USD 100 billion but confirms its standing as a large-scale pharmaceutical company with strong oncology growth (Padcev/enfortumab vedotin, an antibody-drug conjugate, achieved rapid adoption in bladder cancer). The discontinuation of danuglipron was a significant strategic setback, leaving Pfizer without a GLP-1 programme in the world's fastest-growing peptide market. The company is exploring lotiglipron as an alternative oral GLP-1 candidate. Pfizer's peptide-relevant pipeline includes oncology antibody-drug conjugates (which utilise peptide linker chemistry) and its manufacturing expertise in complex molecule synthesis gives it infrastructure that could support future peptide manufacturing partnerships or in-licensing opportunities.

Quick Facts

• HQ: New York City, New York, USA
• FY2024 Revenue: USD 63.6B FY2024; declining post-COVID; oncology growing; danuglipron oral GLP-1 discontinued 2024
• Key Peptide Products: Somavert (pegvisomant — GH receptor antagonist), Genotropin (somatropin — growth hormone peptide), BNT116/mRNA oncology vaccines, historical insulin franchise, Lupron (leuprolide — US rights via Abbvie partnership)
• Therapeutic Segments: Oncology (Ibrance, Xtandi partnership, Padcev, Lorbrena); Vaccines & Antivirals; Primary Care; Hospital
• 2024–2026 Update: FY2024 total revenue USD 63.6B (post-COVID decline trend); danuglipron (oral GLP-1) Phase 2b discontinued Dec 2023 due to GI tolerability; Padcev (antibody-drug conjugate) growing strongly in bladder cancer; Genotropin stable GH peptide franchise; significant cost restructuring ongoing

Ferring Pharmaceuticals is the most specialised pure-play peptide pharmaceutical company in the top 10, operating entirely in reproductive medicine and hormone therapy niches where its peptide drug expertise is unmatched. Founded in 1950 by Dr. Frederik Paulsen Sr. in Malmö, Sweden, and now headquartered in Saint-Prex, Switzerland, Ferring remains a fully private, family-controlled company that has deliberately avoided the pressures of public markets to maintain a long-term research focus. Its entire business model is built around peptide hormones and their synthetic analogues: gonadotropins for fertility treatment (Menopur), GnRH antagonists for fertility and oncology (Cetrotide, Ganirelix, Firmagon/degarelix), and synthetic vasopressin analogues for diabetes insipidus and nocturia (DDAVP/desmopressin).

Ferring's competitive position is defined by market leadership in IVF/ART pharmaceutical protocols — where its Cetrotide (cetrorelix) and Menopur (FSH/LH) products are the standard of care in most IVF stimulation protocols globally. The global IVF market is structurally growing as delayed parenthood, improved insurance reimbursement, and fertility tourism expand the patient population. In urology, Firmagon (degarelix) is a pure GnRH antagonist (as opposed to GnRH agonist like leuprolide) for prostate cancer, offering the clinical advantage of immediate testosterone suppression without the initial flare associated with GnRH agonists. A separate strategic bet is Rebyota — the first FDA-approved live biotherapeutic product for recurrent Clostridioides difficile infection — marking Ferring's entry into the microbiome therapy space and diversifying its peptide-centric portfolio.

Quick Facts

• HQ: Saint-Prex, Switzerland
• FY2024 Revenue: ~CHF 2.5B (~USD 2.8B) est. FY2024 (private; not publicly disclosed); reproductive medicine dominant
• Key Peptide Products: Menopur (menotropins — FSH/LH peptide for IVF/ART), Cetrotide (cetrorelix — GnRH antagonist), Orgalutran (ganirelix — GnRH antagonist), Minirin/DDAVP (desmopressin — synthetic vasopressin), Firmagon (degarelix — GnRH antagonist for prostate cancer), Obe-cx43 (obeticholic acid CBX — pipeline)
• Therapeutic Segments: Reproductive Medicine & Maternal Health (IVF/ART); Urology (prostate cancer, OAB, nocturia); Gastroenterology (Rebyota — microbiome)
• 2024–2026 Update: Firmagon growing in prostate cancer GnRH antagonist market; Rebyota (fecal microbiota suspension) launched in US 2023 — first approved FMT product; reproductive medicine IVF protocols core franchise; private structure maintains strategic flexibility; fertility tourism growth driving IVF drug demand globally

Teva Pharmaceutical Industries (NYSE: TEVA) ranks ninth in this report, representing the peptide market's most important generics and specialty hybrid perspective. Headquartered in Tel Aviv, Teva is the world's largest generic pharmaceutical company and a significant specialty innovator, with a particular position in the peptide therapy market through Copaxone (glatiramer acetate) — a synthetic peptide copolymer that has been the world's best-selling multiple sclerosis treatment for two decades — and AJOVY (fremanezumab), a CGRP-targeting monoclonal antibody for migraine prevention that occupies the neurological peptide signalling space.

Teva's FY2024 revenues of USD 16.5 billion (+7%) reflect the early stages of a commercial recovery from the financial restructuring of 2017–2022. Copaxone — once a USD 4 billion annual product — has declined sharply as generic glatiramer acetate and competing MS therapies have taken share, but it remains a meaningful contributor. AJOVY (fremanezumab), competing against Aimovig (Amgen/Novartis) and Ajovy (Teva) in the CGRP migraine prevention class, is growing and demonstrates Teva's capacity to develop innovative peptide-adjacent biologics. Crucially for the 2026–2031 forecast period, Teva's generic manufacturing infrastructure — which includes peptide synthesis capabilities — positions it as a potential major player in the semaglutide and tirzepatide generic market that will open following patent expiries (semaglutide: US patent 2032; tirzepatide: ~2036).

Quick Facts

• HQ: Tel Aviv, Israel
• FY2024 Revenue: USD 16.5B FY2024 (+7% YoY); AJOVY USD ~360M; innovative medicines growing; generic biosimilars expanding
• Key Peptide Products: AJOVY (fremanezumab — CGRP monoclonal antibody for migraine prevention), Copaxone (glatiramer acetate — synthetic peptide for multiple sclerosis, declining due to generics), synthetic peptide generics manufacturing, peptide biosimilar capabilities
• Therapeutic Segments: Innovative Medicines (AJOVY, AUSTEDO); Generic Medicines (global); Biosimilars
• 2024–2026 Update: FY2024 revenue USD 16.5B (+7%); AJOVY growing in CGRP migraine space; Copaxone continuing decline as generic glatiramer erodes share; generic biosimilar peptide capabilities building; launched semaglutide generics preparation (post 2032 patent expiry anticipation); significant debt reduction ongoing

Amgen Inc. (NASDAQ: AMGN) is ranked tenth in this report on the basis of its growing overall pharmaceutical scale and, most significantly, its uniquely differentiated MariTide — a peptide-antibody conjugate that is the most scientifically interesting GLP-1-adjacent molecule in late-stage development. Headquartered in Thousand Oaks, California, Amgen is a pioneering biotechnology company founded in 1980, whose core expertise in recombinant protein engineering has been applied to create MariTide: a multispecific molecule that simultaneously activates the GLP-1 receptor (driving weight loss) and antagonises the GIP receptor — the opposite mechanism to tirzepatide — conjugated to an Fc region for extended half-life enabling monthly or less frequent dosing.

Amgen's FY2024 revenues of USD 33.4 billion grew 19% year-on-year, supported by the Horizon Therapeutics acquisition (bringing Tepezza for thyroid eye disease and other rare disease assets). The MariTide Phase 2 data presented in November 2024 were highly significant: MariTide demonstrated robust weight loss at 52 weeks with no plateau — meaning continued weight loss trajectory at the end of the study period, unlike semaglutide and tirzepatide which show plateau effects — and significant improvements in cardiometabolic parameters. Its dosing frequency of monthly or less frequent injections represents a potential patient experience advantage over Ozempic's weekly injection if Phase 3 data confirm Phase 2 results. The MARITIME Phase 3 programme is actively enrolling across obesity, OSA, and T2D indications. If successful, MariTide could challenge the Novo Nordisk/Eli Lilly duopoly — which the report notes holds 57.4% of the market — and reshape the competitive landscape by 2029–2031.

Quick Facts

• HQ: Thousand Oaks, California, USA
• FY2024 Revenue: USD 33.4B FY2024 (+19% YoY); MariTide Phase 2 obesity data positive; Tepezza, Tezspire growing
• Key Peptide Products: MariTide (maridebart cafraglutide — GLP-1R agonist/GIPR antagonist peptide-antibody conjugate, Phase 2/3 pipeline for obesity), Nplate (romiplostim — Fc-peptide fusion for ITP), Tezspire (tezepelumab, with AstraZeneca), Aimovig (erenumab — CGRP receptor mAb for migraine)
• Therapeutic Segments: General Medicine (Repatha, Aimovig, Otezla); Oncology (Blincyto, Lumakras, Kyprolis); Bone Health; Rare Disease (Tepezza, UPLIZNA)
• 2024–2026 Update: FY2024 total revenue USD 33.4B (+19%); MariTide Phase 2: robust weight loss at 52 weeks with NO plateau — unique differentiation vs Ozempic/Zepbound; first monthly-or-less-frequent obesity drug in Phase 2; Phase 3 programme initiated across multiple indications including OSA; Horizon Therapeutics (Tepezza) integration delivering growth

• Semaglutide became the world's highest-revenue drug (2024): Combined Ozempic + Wegovy sales of ~USD 26 billion in 2024 made semaglutide the best-selling drug globally — displacing Keytruda and Humira. This milestone marks the first time a peptide drug has topped the global sales rankings.
• Tirzepatide's SURMOUNT-5 head-to-head vs semaglutide (2025): Zepbound demonstrated 47% greater relative weight loss vs Wegovy in a direct Phase 3b comparison — the most commercially significant clinical trial result in the obesity market, directly challenging Novo Nordisk's market leadership.
• Obesity indication approval expanded GLP-1 addressable market by an estimated 10-15×: The US obesity drug market was approximately USD 2 billion in 2021 before Wegovy's approval. By 2024 it exceeded USD 15 billion and is forecast to surpass USD 50 billion by 2030 — entirely driven by GLP-1/GIP peptide therapies.
• Pfizer's danuglipron oral GLP-1 discontinued (late 2023): The failure of Pfizer's oral GLP-1 programme eliminated what would have been the most significant challenge to Novo Nordisk's oral semaglutide (Rybelsus) advantage, reducing competitive pressure on injectable-to-oral transition.
• GLP-1 supply constraints limited market growth 2022–2024: Novo Nordisk and Eli Lilly both experienced significant supply constraints limiting GLP-1 prescription fulfilment, particularly Wegovy. Both companies responded with multi-billion dollar manufacturing capacity expansions. The constraints began resolving in 2024; full supply normalisation is expected by 2026.
• Novartis Pluvicto established radioligand therapy as a commercial reality (2022+): Lutetium-177 PSMA-617 (Pluvicto) for metastatic castration-resistant prostate cancer achieved rapid adoption post-2022 launch, validating the peptide receptor radionuclide therapy platform and creating a template for multiple follow-on radioligand therapy programmes.
• Amgen's MariTide Phase 2 showed no weight loss plateau at 52 weeks (Nov 2024): The absence of a weight loss plateau effect — which both semaglutide and tirzepatide display — would be a clinically meaningful differentiation if confirmed in Phase 3, potentially enabling greater sustained weight loss. Monthly or less frequent dosing adds further patient convenience differentiation.
• India and emerging markets emerging as biosimilar GLP-1 production hubs: India's pharmaceutical manufacturing capability — established through insulin biosimilars — is being retargeted toward semaglutide biosimilar production ahead of the 2032 US patent expiry. Companies including Biocon, Dr. Reddy's, and Sun Pharma are advancing GLP-1 biosimilar programmes.

1. The GLP-1 Revolution: Beyond Diabetes and Obesity

Semaglutide and tirzepatide have demonstrated efficacy across an expanding universe of indications that extends far beyond their initial diabetes approvals. Cardiovascular outcomes (Ozempic for heart attack and stroke reduction; FDA-approved), chronic kidney disease (Ozempic; label expansion 2024), obstructive sleep apnea (Zepbound; FDA-approved December 2024), non-alcoholic fatty liver disease (NASH/MASH; trials ongoing), and neurodegenerative disease (Alzheimer's; Phase 2 signals) are all being actively studied. Each positive data readout dramatically expands the addressable patient population and further extends the revenue growth horizon for GLP-1/GIP peptide therapy well beyond the 2031 forecast period.

2. The Oral GLP-1 Race

Novo Nordisk's oral semaglutide (Rybelsus) demonstrated that GLP-1 receptor agonists can be delivered orally — overcoming the injection barrier that has limited adoption, particularly in developing markets and among needle-averse patients. Rybelsus's 2023 revenue exceeded USD 2 billion. The company is advancing higher-dose oral semaglutide formulations targeting obesity-level weight loss. With Pfizer's danuglipron discontinued and Lilly's orforglipron in Phase 3, the oral GLP-1 race is intensifying. Volume CAGR of 23.95% for the GLP-1/GIP segment through 2031 partly reflects the anticipated expansion driven by oral formulations reaching price-sensitive and needle-averse populations globally.

3. Next-Generation Multi-Agonist Peptides

The progression from GLP-1 mono-agonists (semaglutide, liraglutide) to GLP-1/GIP dual agonists (tirzepatide) to triple agonists (retatrutide: GLP-1/GIP/glucagon, Lilly Phase 3) represents a systematic intensification of multi-receptor engagement to drive superior metabolic outcomes. Retatrutide Phase 2 data showed approximately 24% weight loss at 48 weeks — superior to tirzepatide at the same timepoint. CagriSema (semaglutide + amylin analogue cagrilintide) delivered 22.7% weight loss in Phase 3. This pipeline indicates that the performance ceiling for peptide-based obesity therapeutics has not yet been reached, sustaining investor and commercial expectations well into the 2030s.

4. Biosimilar and Generic Pressure Reshaping the Competitive Landscape

The semaglutide patent expires in the US in 2032, with tirzepatide approximately four years later. The biosimilar/generic entry timeline will fundamentally reshape market economics — driving the volume CAGR of 21.24% through 2031 even as price compression limits value CAGR to 14.74%. India, South Korea, and Chinese pharmaceutical companies are the most advanced in GLP-1 biosimilar development. The report's finding that volume growth is expected to substantially outpace value growth through 2031 reflects the early stages of this pricing pressure dynamic, as compounded semaglutide (available through 503B pharmacies during the shortage period) and international low-cost alternatives begin to set price expectations.

5. Asia-Pacific as the Structural Demand Engine

China's 140 million type 2 diabetics, India's rapidly expanding middle class, and Japan's aging population collectively represent the most important geographic growth opportunity in the global peptide therapy market. The NMPA's 2021 approval of Ozempic in China and PMDA's 2021 and 2023 approvals of Ozempic and Wegovy in Japan are driving adoption in the world's most populous diabetes markets. According to the Navadhi Global Peptide Therapy Market Strategic Research Report 2026-2031, India's emergence as both a high-growth demand market (19.89% CAGR) and a biosimilar manufacturing hub creates a unique dual role — as GLP-1 costs decline through Indian biosimilar production, the addressable patient population in price-sensitive Asian and African markets will expand dramatically, driving the 21.24% volume CAGR through 2031.